Hayslip, John W <br/><br/>
Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.  [electronic resource] 

 -  Clinical lymphoma & myeloma  Jun 2008 
 - 166-70 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1557-9190 
<br/><br/><label>Standard No.: </label>10.3816/CLM.2008.n.020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Chemotherapy, Adjuvant--economics<br/>Costs and Cost Analysis--methods<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Lymphoma, Follicular--drug therapy<br/>Male<br/>Models, Biological<br/>Prednisone--administration & dosage<br/>Remission Induction--methods<br/>Rituximab<br/>Survival Rate<br/>United States<br/>Vincristine--administration & dosage